[Anti-tyrosine kinase: the beginning of molecular therapies of cancer and initial results].
作者信息
Guilhot F
机构信息
Service d'oncologie hématologique et de thérapie cellulaire, CHU La Milétrie, 86021 Poitiers.
出版信息
Bull Cancer. 2001 Jul;88(7):659-60.
PMID:11495817
Abstract
摘要
相似文献
1
[Anti-tyrosine kinase: the beginning of molecular therapies of cancer and initial results].
Bull Cancer. 2001 Jul;88(7):659-60.
2
[Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia].
Bull Cancer. 2001 Jul;88(7):651-8.
3
Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
Oncogene. 2002 Dec 9;21(56):8541-6. doi: 10.1038/sj.onc.1206081.
4
New-age drug meets resistance.
Nature. 2001 Jul 19;412(6844):281-2. doi: 10.1038/35085665.
5
Applying the discovery of the Philadelphia chromosome.
J Clin Invest. 2007 Aug;117(8):2067-74. doi: 10.1172/JCI31988.
6
Imatinib and chronic-phase leukemias.
N Engl J Med. 2002 Jul 4;347(1):67-8. doi: 10.1056/NEJM200207043470116.
7
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
N Engl J Med. 2001 Apr 5;344(14):1084-6. doi: 10.1056/NEJM200104053441409.
8
Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Leuk Res. 2008 Nov;32(11):1724-34. doi: 10.1016/j.leukres.2008.04.023. Epub 2008 Jul 7.
9
New tyrosine kinase inhibitors in chronic myeloid leukemia.
Haematologica. 2005 Apr;90(4):534-41.
10
Current treatment approaches for chronic myelogenous leukemia.
Cancer J. 2001 Jul-Aug;7 Suppl 1:S14-8.
Zotero 插件